Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

ABSTRACT: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

PROVIDER: PRJNA476140 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7344550.fastq.gz	Fastqsanger.gz
	SRR7344550_1.fastq.gz	Fastqsanger.gz
	SRR7344550_2.fastq.gz	Fastqsanger.gz
	SRR7344560_1.fastq.gz	Fastqsanger.gz
	SRR7344560_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 88

Similar Datasets

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Project description:Immune checkpoint blockade (ICB) therapy provides remarkable clinical gains, where melanoma is at the forefront of its success. However, only a subset of patients with advanced tumors currently benefit from these therapies, which at times incur considerable side-effects and costs. Constructing such predictors of patient’s response has remained a serious challenge due to the complexity of the immune response and the shortage of large ICB-treated patient cohorts including both omics and response data. Here we build IMPRES, a predictor of ICB-response in melanoma which encompasses 15 pairwise transcriptomics relations between immune checkpoint genes. It is based on two key conjectures: (a) immune mechanisms underlining spontaneous regression in neuroblastoma can predict ICB response in melanoma, and (b) key immune interactions can be captured via specific pairwise relations of immune checkpoint genes’ expression. IMPRES is validated on 9 published datasets1–6 and on a newly generated dataset of 31 tumor samples treated with anti-PD-1 and 10 tumor samples treated with anti-CTLA-4 (some of these are treated with both antibodies), spanning 297 samples in total. It achieves an overall accuracy of AUC=0.83, outperforming existing predictors, capturing almost all true responders while misclassifying less than half of the non-responders. Future studies are warranted to determine the value of the approach presented here in other cancer types.

2018-08-20 | GSE115821 | GEO

DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma

Project description:DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma

| PRJNA733214 | ENA

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Project description: Not available

| S-EPMC6693632 | biostudies-literature

Neoadjuvant Pepinemab with Immune Checkpoint Blockade Remodels the Tumor Microenvironment in Metastatic Melanoma

Project description:Neoadjuvant Pepinemab with Immune Checkpoint Blockade Remodels the Tumor Microenvironment in Metastatic Melanoma

| PRJNA1469599 | ENA

Immune Checkpoint Blockade Activates Macrophages and Remodels the Lymph Node Microenvironment in Melanoma Metastasis

Project description:The factors that drive therapeutic resistance and variable patient response to immune checkpoint blockade therapies within the metastatic lymph nodes are poorly understood. Activation of lymph node immune cells can promote effective immune checkpoint blockade responses or alternately enforce immunosuppression. Here we investigated a murine model of lymph node melanoma metastasis that was amenable to combination immune checkpoint blockade at the cellular, protein, and transcriptional level. Checkpoint blockade spatially reorganized and activated T and B lymphocytes as well as lymph node stromal cells. Notably, myeloid cells, key mediators of lymph node immune function, were reprogrammed to an immunostimulatory phenotype upon checkpoint blockade. Our data supports a model in which immunostimulatory macrophages are induced and macrophage-mediated T cell suppression is released during effective immunotherapy.

2026-09-06 | GSE334818 | GEO

Antibody-lectin chimeras for glyco-immune checkpoint blockade

Project description:Despite the curative potential of checkpoint blockade immunotherapy, most patients remain unresponsive to existing treatments. Glyco-immune checkpoints – interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors – have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular platform for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin “decoy receptor” domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate anticancer immune responses including phagocytosis and cytotoxicity, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumor and immune cell subsets as well as glyco-immune checkpoints, and therefore represent a new modality for cancer immunotherapy.

2025-08-13 | PXD063934 | Pride

Neoadjuvant Pepinemab with Immune Checkpoint Blockade Remodels the Tumor Microenvironment in Metastatic Melanoma

Project description:Neoadjuvant immune checkpoint inhibitors (ICIs) improve event-free survival in metastatic melanoma, yet resistance and recurrence remain common. We evaluated pepinemab, a Semaphorin 4D (SEMA4D)–blocking antibody, in combination with nivolumab and/or ipilimumab in a phase II neoadjuvant biomarker trial for patients with resectable metastatic melanoma. Patients received two neoadjuvant doses followed by curative-intent surgery and one year of adjuvant nivolumab. Pepinemab-containing regimens did not increase immune-related adverse events and did not delay or preclude curative-intent surgical resection. Mechanistically, pepinemab plus ICI was associated with immune remodeling features, including increased T and B cell infiltration and enrichment of type 1 conventional dendritic cells. These changes were associated with the formation of mature lymphoid aggregates resembling tertiary lymphoid structures that contained clonally expanded T cell receptor repertoires, consistent with localized cytotoxic activity. Together, these findings support further evaluation of SEMA4D blockade as a strategy to enhance neoadjuvant immunotherapy in melanoma.

2026-08-20 | GSE332987 | GEO

Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study

Project description:<p>Blockade of T cell coinhibitory molecules such as CTLA-4 and PD-1, can activate T cell antitumor response. Although these immune checkpoint blockades (CTLA-4 blockade and PD-1 blockade) have shown durable response, response rate is modest. Therefore, there is a need to find stable biomarkers predictive of response to immune checkpoint blockades and to understand underlying resistance mechanisms. We collected longitudinal tumor biopsies from a cohort of metastatic melanoma patients treated with sequential immune checkpoint blockades and performed whole exome sequencing of this cohort. The comprehensive genomic characterization of tumors enabled identification of higher copy number loss burden as a resistance mechanism and clonal T cell repertoire as a predictive biomarker.</p>

| phs001425 | dbGaP

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Project description: Not available

| S-EPMC9639231 | biostudies-literature

CRLF1 contributes to acquired resistance to immune checkpoint blockade in mismatch repair-deficient colorectal cancer

Project description:Immune checkpoint blockade (ICB) has greatly improved survival for mismatch repair-deficient metastatic colorectal cancer (dMMR/dCRC) patients, yet 40%–60% either fail to respond or develop acquired resistance (AR). This study established an anti-PD-1-resistant dCRC model and identified cytokine receptor-like factor 1 (CRLF1) as a key mediator of AR, whose upregulation impairs CD8+ T-cell anti-tumor immunity.

| PXD077703 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data